The Global Pharmaceutical Manufacturing Market Size accounted for USD 425.9 Billion in 2021 and is estimated to achieve a market size of USD 1,599.9 Billion by 2030 growing at a CAGR of 15.9% from 2022 to 2030. Increasing prevalence of chronic disorders is primarily fueling the pharmaceutical manufacturing market growth. Additionally, rising number of clinical trials is a prominent pharmaceutical manufacturing market trend that is strengthening the industry growth. Furthermore, growing emphasis on outsourcing drug manufacturing is expected to open up new growth prospects for the industry in the coming years.
Pharmaceutical Manufacturing Market Report Key Highlights
- Global pharmaceutical manufacturing market revenue is poised to garner USD 1,599.9 Billion by 2030 with a CAGR of 15.9% from 2022 to 2030
- Growing elderly population fuels the pharmaceutical manufacturing market growth
- According to the World Bank Statistics 2019, there were 703 million people aged 65 years or over in the world
- North America is the leading region with over 37% shares in 2021
- Asia-Pacific is likely to attain a significant CAGR from 2022 to 2030
- Based on route of administration segment, oral attained more than 55% of the total market share in 2021
Pharmaceutical manufacturing comprises the physical process of manufacturing pharmaceutical drugs. The process includes blending, compression, filtration, heating, encapsulation, shearing, tableting, granulation, coating, and drying. Pharmaceutical manufacturing is said to be a conservative business with low readiness and appetite for changes, assuming risks or embarking on new technological strategies and approaches. Pharmaceutical manufacturing has evolved with the increased focus on science and engineering principles.
Global Pharmaceutical Manufacturing Market Dynamics
Market Drivers
- Growing pharmaceutical R&D spending
- Increasing incidences of chronic disorders
- Growing focus on outsourcing manufacturing activities
- Advancements in pharmaceutical manufacturing technologies
Market Restraints
- Pricing pressure on pharma companies
- Challenges pertaining pharma supply chain
Market Opportunities
- Growing number of clinical trials
- Increasing investments and growing government support
Pharmaceutical Manufacturing Market Report Coverage
| Market |
Pharmaceutical Manufacturing Market |
| Pharmaceutical Manufacturing Market Size 2021 |
USD 425.9 Billion |
| Pharmaceutical Manufacturing Market Forecast 2030 |
USD 1,599.9 Billion |
| Pharmaceutical Manufacturing Market CAGR During 2022 - 2030 |
15.9% |
| Pharmaceutical Manufacturing Market Analysis Period |
2018 - 2030 |
| Pharmaceutical Manufacturing Market Base Year |
2021 |
| Pharmaceutical Manufacturing Market Forecast Data |
2022 - 2030 |
| Segments Covered |
By Formulation, By Route of Administration, By Prescription, By Drug Development, By Distribution Channel, And By Geography
|
| Pharmaceutical Manufacturing Market Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lonza, Merck & Co. Inc., Novartis AG, Pfizer, Inc., Sanofi SA, and others. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Pharmaceutical Manufacturing Market Insights
The increasing spending in the pharmaceutical R&D sector along with the advancements in pharmaceutical manufacturing technologies is driving the market growth. For instance, the FDA’s Center for Drug Evaluation and Research (CDER) has approved 46 new molecular entities (NMEs) in 2017 and the entity number got doubled in 2016. The rising focus on the healthcare needs of emerging nations across the globe is bolstering the market value. The growing geriatric population and incidence rate of chronic disorders due to changing lifestyle is further propelling the market value. Furthermore, the increasing number of clinical trials along with the increasing investment and funding programs across the pharmaceutical manufacturing industry is projected to create potential opportunities over the forecast period from 2022 to 2030.
On the other side, patent expiration of most profitable drugs and pricing pressures on pharmaceutical companies is estimated to hinder the growth to an extent over the forecast period from 2022 to 2030.
Pharmaceutical Manufacturing Market Segmentation
The worldwide pharmaceutical manufacturing market is split based on formulation, route of administration, prescription, drug development, distribution channel, and geography.
Pharmaceutical Manufacturing Market By Formulation
- Tablets
- Capsules
- Injectable
- Sprays Suspensions
- Powders
- Other Formulations
According to our pharmaceutical manufacturing industry analysis, the tablet formulation occupied the majority of the share in 2021. The widespread availability of tablets in different shapes, sizes, and colors is a prominent reason for this segmental growth. In addition, the arrival of 3D-printed tablets along with the growing trend of personalized medicines are boosting the market share.
Pharmaceutical Manufacturing Market By Route of Administration
- Oral
- Topical
- Parenteral
- Inhalations
- Others
In 2021 the oral segment by route of administration is leading the market with maximum revenue share. The benefits associated with the oral dosage of drugs like affordability, ease of manufacturing, and patient-friendly among others is contributing to the segmental market value. The advancement in the drug delivery technology for oral administration of drugs like sustained release dosage formulations and targeted drug delivery is further bolstering the segmental market value.
Pharmaceutical Manufacturing Market By Prescription
- Prescription Medicines
- Over-the-counter (OTC) Medicines
According to our pharmaceutical manufacturing market forecast, prescription medicines acquired more than 80% of the pharmaceutical manufacturing market share in 2021. This massive share of prescription drugs is because of the rising prescription drug expenditures throughout the world. A gradual shift of consumers towards over-the-counter (OTC) medicines is anticipated to witness a noteworthy growth rate in the coming years.
Pharmaceutical Manufacturing Market By Drug Development
In 2021, the outsource drug development accumulated the principal market share. Several advantages associated with outsourcing operations are projected to propel the market forward at a rapid rate in the coming years. The in-house drug development also gathered a significant share in 2021. The use of in-house infrastructure and knowledge by large pharmaceutical corporations for drug development is the primary reason for multi-dose systems' significant market dominance.
Pharmaceutical Manufacturing Market By Distribution Channel
Based on the distribution channel, the offline segment will account for more than 70% of the overall market. As medical costs and healthcare coverage have risen, more people have moved their preferences toward self-medication for minor health conditions. However, the advent of COVID-19 and rising consumer preference toward e-commerce will boost the online distribution channel segment in the coming years.
Pharmaceutical Manufacturing Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
The Middle East & Africa (MEA)
- Gulf Cooperation Council (GCC)
- South Africa
- Rest of the Middle East & Africa (ME&A)
North America accounted for the maximum revenue share in the pharmaceutical manufacturing market
In 2021, North America is leading the pharmaceutical manufacturing market with maximum revenue share (%), and the region along with its major economies projected to continue with its dominance over the estimated period from 2022 to 2030. The presence of major players and the well-established healthcare sector in the region is supporting its dominance. Additionally, the presence of a high-income population which is spending on their health is another factor giving momentum to the market value.
Asia Pacific is estimated to experience fastest growth over the forecast timeframe from 2020 to 2027
The rapidly developing pharmaceutical sector of the developing economies of the region is primarily supporting market growth. The COVID-19 pandemic has also given traction to the regional market value, as the developing economies including India and China have invested their time and money in the development of vaccination in large quantities which is another consideration for the regional market growth. The increasing number of regional players along with the rising focus of major global players on the developing markets of the region is additionally proliferating the regional pharmaceutical manufacturing market value.
Pharmaceutical Manufacturing Market Players
Some of the top pharmaceutical manufacturing companies offered in the professional report include AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lonza, Merck & Co. Inc., Novartis AG, Pfizer, Inc., and Sanofi SA.
CHAPTER 1. Industry Overview of Pharmaceutical Manufacturing Market
1.1. Definition and Scope
1.1.1. Definition of Pharmaceutical Manufacturing
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Pharmaceutical Manufacturing Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Pharmaceutical Manufacturing Market By Formulation
1.2.3. Pharmaceutical Manufacturing Market By Route of Administration
1.2.4. Pharmaceutical Manufacturing Market By Prescription
1.2.5. Pharmaceutical Manufacturing Market By Drug Development
1.2.6. Pharmaceutical Manufacturing Market By Distribution Channel
1.2.7. Pharmaceutical Manufacturing Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Pharmaceutical Manufacturing Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Pharmaceutical Manufacturing Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2021
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2021
4.2. R&D Status of Major Manufacturers in 2021
CHAPTER 5. Pharmaceutical Manufacturing Market By Formulation
5.1. Introduction
5.2. Pharmaceutical Manufacturing Revenue By Formulation
5.2.1. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast, By Formulation, 2018-2030
5.2.2. Tablets
5.2.2.1. Tablets Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.3. Capsules
5.2.3.1. Capsules Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.4. Injectable
5.2.4.1. Injectable Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.5. Sprays
5.2.5.1. Sprays Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.6. Suspensions
5.2.6.1. Suspensions Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.7. Powders
5.2.7.1. Powders Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.8. Others
5.2.8.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 6. Pharmaceutical Manufacturing Market By Route of Administration
6.1. Introduction
6.2. Pharmaceutical Manufacturing Revenue By Route of Administration
6.2.1. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast, By Route of Administration, 2018-2030
6.2.2. Topical
6.2.2.1. Topical Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.3. Parenteral
6.2.3.1. Parenteral Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.4. Oral
6.2.4.1. Oral Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.5. Inhalations
6.2.5.1. Inhalations Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.6. Others
6.2.6.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 7. Pharmaceutical Manufacturing Market By Prescription
7.1. Introduction
7.2. Pharmaceutical Manufacturing Revenue By Prescription
7.2.1. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast, By Prescription, 2018-2030
7.2.2. Prescription Medicines
7.2.2.1. Prescription Medicines Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
7.2.3. Over-the-counter (OTC) Medicines
7.2.3.1. Over-the-counter (OTC) Medicines Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 8. Pharmaceutical Manufacturing Market By Drug Development
8.1. Introduction
8.2. Pharmaceutical Manufacturing Revenue By Drug Development
8.2.1. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast, By Drug Development, 2018-2030
8.2.2. Outsource
8.2.2.1. Outsource Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
8.2.3. In-house
8.2.3.1. In-house Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 9. Pharmaceutical Manufacturing Market By Distribution Channel
9.1. Introduction
9.2. Pharmaceutical Manufacturing Revenue By Distribution Channel
9.2.1. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast, By Distribution Channel, 2018-2030
9.2.2. Online
9.2.2.1. Online Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
9.2.3. Offline
9.2.3.1. Offline Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 10. North America Pharmaceutical Manufacturing Market By Country
10.1. North America Pharmaceutical Manufacturing Market Overview
10.2. U.S.
10.2.1. U.S. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
10.2.2. U.S. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.2.3. U.S. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
10.2.4. U.S. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
10.2.5. U.S. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.3. Canada
10.3.1. Canada Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
10.3.2. Canada Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.3.3. Canada Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
10.3.4. Canada Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
10.3.5. Canada Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.4. North America PEST Analysis
CHAPTER 11. Europe Pharmaceutical Manufacturing Market By Country
11.1. Europe Pharmaceutical Manufacturing Market Overview
11.2. U.K.
11.2.1. U.K. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
11.2.2. U.K. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.2.3. U.K. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
11.2.4. U.K. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
11.2.5. U.K. Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.3. Germany
11.3.1. Germany Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
11.3.2. Germany Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.3.3. Germany Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
11.3.4. Germany Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
11.3.5. Germany Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.4. France
11.4.1. France Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
11.4.2. France Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.4.3. France Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
11.4.4. France Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
11.4.5. France Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.5. Spain
11.5.1. Spain Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
11.5.2. Spain Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.5.3. Spain Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
11.5.4. Spain Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
11.5.5. Spain Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.6. Rest of Europe
11.6.1. Rest of Europe Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
11.6.2. Rest of Europe Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.6.3. Rest of Europe Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
11.6.4. Rest of Europe Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
11.6.5. Rest of Europe Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.7. Europe PEST Analysis
CHAPTER 12. Asia Pacific Pharmaceutical Manufacturing Market By Country
12.1. Asia Pacific Pharmaceutical Manufacturing Market Overview
12.2. China
12.2.1. China Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
12.2.2. China Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.2.3. China Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
12.2.4. China Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
12.2.5. China Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.3. Japan
12.3.1. Japan Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
12.3.2. Japan Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.3.3. Japan Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
12.3.4. Japan Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
12.3.5. Japan Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.4. India
12.4.1. India Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
12.4.2. India Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.4.3. India Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
12.4.4. India Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
12.4.5. India Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.5. Australia
12.5.1. Australia Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
12.5.2. Australia Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.5.3. Australia Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
12.5.4. Australia Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
12.5.5. Australia Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.6. South Korea
12.6.1. South Korea Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
12.6.2. South Korea Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.6.3. South Korea Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
12.6.4. South Korea Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
12.6.5. South Korea Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.7. Rest of Asia-Pacific
12.7.1. Rest of Asia-Pacific Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
12.7.2. Rest of Asia-Pacific Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.7.3. Rest of Asia-Pacific Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
12.7.4. Rest of Asia-Pacific Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
12.7.5. Rest of Asia-Pacific Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.8. Asia Pacific PEST Analysis
CHAPTER 13. Latin America Pharmaceutical Manufacturing Market By Country
13.1. Latin America Pharmaceutical Manufacturing Market Overview
13.2. Brazil
13.2.1. Brazil Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
13.2.2. Brazil Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
13.2.3. Brazil Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
13.2.4. Brazil Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
13.2.5. Brazil Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
13.3. Mexico
13.3.1. Mexico Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
13.3.2. Mexico Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
13.3.3. Mexico Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
13.3.4. Mexico Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
13.3.5. Mexico Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
13.4. Rest of Latin America
13.4.1. Rest of Latin America Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
13.4.2. Rest of Latin America Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
13.4.3. Rest of Latin America Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
13.4.4. Rest of Latin America Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
13.4.5. Rest of Latin America Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
13.5. Latin America PEST Analysis
CHAPTER 14. Middle East & Africa Pharmaceutical Manufacturing Market By Country
14.1. Middle East & Africa Pharmaceutical Manufacturing Market Overview
14.2. GCC
14.2.1. GCC Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
14.2.2. GCC Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
14.2.3. GCC Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
14.2.4. GCC Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
14.2.5. GCC Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
14.3. South Africa
14.3.1. South Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
14.3.2. South Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
14.3.3. South Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
14.3.4. South Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
14.3.5. South Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
14.4. Rest of Middle East & Africa
14.4.1. Rest of Middle East & Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Formulation, 2018-2030
14.4.2. Rest of Middle East & Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
14.4.3. Rest of Middle East & Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Prescription, 2018-2030
14.4.4. Rest of Middle East & Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Drug Development, 2018-2030
14.4.5. Rest of Middle East & Africa Pharmaceutical Manufacturing Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
14.5. Middle East & Africa PEST Analysis
CHAPTER 15. Player Analysis Of Pharmaceutical Manufacturing Market
15.1. Pharmaceutical Manufacturing Market Company Share Analysis
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Mergers And Acquisition In Global Pharmaceutical Manufacturing Market
15.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 16. Company Profile
16.1. AstraZeneca
16.1.1. Company Snapshot
16.1.2. Business Overview
16.1.3. Financial Overview
16.1.3.1. Revenue (USD Billion), 2021
16.1.3.2. AstraZeneca 2021 Pharmaceutical Manufacturing Business Regional Distribution
16.1.4. Product /Service and Specification
16.1.5. Recent Developments & Business Strategy
16.2. Eli Lilly and Company
16.3. F. Hoffmann-La Roche Ltd.
16.4. GlaxoSmithKline plc
16.5. Johnson & Johnson
16.6. Lonza
16.7. Merck & Co. Inc.
16.8. Novartis AG
16.9. Pfizer, Inc.
16.10. Sanofi SA
